Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Later bookings dent profits at On The Beach, shares slide

(Sharecast News) - Shares in On The Beach Group tumbled in morning trading on Monday, after it confirmed that full-year profits would miss forecasts. Updating on trading, the online package holiday specialist said it had been a "record" year, with the total transaction value up 11% at £1.23bn and summer 2025 bookings 12% stronger year-on-year. Winter bookings were also ahead 12%.

However, bookings for summer 2026 were faring less well, as consumers opted to book far nearer to departure.

The group also announced it would wind down Classic Collection, its business-to-business brand, allowing it to focus solely on business-to-consumer. Classic Collection made a "small" loss during the year, it added.

As a result, full-year adjusted pre-tax profits - excluding the B2B operations - are now slated to come in between £34.5m and £35.5m. Consensus, which includes Classic Collection, had been for adjusted pre-tax profits of £38.4m.

As at 0830 BST, shares in On The Beach had slumped 15% at 218.5p.

Shaun Morton, chief executive, said: "Our core B2C business has again outperformed the market, underpinned by the group's asset light, cash-generative model and balance sheet strength.

"It remains clear that customers are still prioritising their holidays, with winter 2025 bookings up 12%, and we remain confident that summer 2026 will continue to build, notwithstanding later booking patterns."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.